Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo - Wikidata - wikimedia - TriplyDB

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

http://www.wikidata.org/entity/Q28476362

about

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin Synergistic and antagonistic drug combinations depend on network topology Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.AKT is a therapeutic target in myeloproliferative neoplasms SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206.Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor Antitumor activity in RAS-driven tumors by blocking AKT and MEK.Animal models in carotenoids research and lung cancer prevention.Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice Trends in Personalized Therapies in Oncology: The (Venture) Capitalist's Perspective Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.Genomic complexity and AKT dependence in serous ovarian cancer.The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer Biomarkers of response to Akt inhibitor MK-2206 in breast cancer MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.Inactivation of AKT induces cellular senescence in uterine leiomyoma.Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

P2860

Q27334924-CD9A508E-AD49-4770-B8BA-533B37FBE516 Q28484890-0076D181-023E-470E-9525-7F48C0B6465A Q28542101-F18AADC6-F526-4336-9B26-C75B39E6A91D Q28547862-81AA4DB7-1114-4A87-9B76-050631075A4D Q30252408-257514A7-D870-4F2B-B935-E1EAA22EE3CD Q33601377-D8D81696-FE57-473E-8508-DD2A685CF0BA Q33623277-9A3A9FA2-1DB1-41D9-8DB8-83696CEC2AE2 Q33911230-8B51CA20-47DD-4331-9CC4-83E63693BCDF Q33992871-7AEDC93C-20E0-4D96-B69B-391E6945A05E Q34273541-09806562-D851-4BE9-A7A8-7657169E1AD2 Q34388048-14684A81-BDBB-45E0-85A9-B1DAF35092C5 Q34436771-90286B4C-1477-4863-9B6E-9FB56E5EF228 Q34793532-F81BE625-AC8F-429A-BAA1-320EA3B888C1 Q34796287-971C896D-A747-48EC-A3ED-9A80CD00B404 Q35103514-08BF9E2B-1630-4636-A387-0B797092D308 Q35182584-8F4E825C-5309-4282-A2EF-FBB962317D6C Q35484895-C32830E9-7147-43D4-AB41-90AB93708CF3 Q35538834-94BECDB3-292C-4AE3-AFAA-5DCBB129E0BD Q35639095-A6064883-90DA-40E9-B670-0CF061CE6986 Q35675442-CFE1F04A-8E40-4CEC-B17D-C269005192E3 Q35743316-89DF373F-2F5A-44D1-AE1F-09DA933E7AF8 Q35744471-E8822864-01B4-44E3-9E54-B8F2A28702FB Q35775241-DB82D93D-6DC0-40B2-90BE-3857A14EFF19 Q35791105-A517EC9C-47B4-461D-8D2F-7648B3C51A90 Q35798191-DFFD38BC-0575-471C-910F-6B60B0A959EC Q35808124-D9C2CA68-68EB-45FB-825F-DBF531115D71 Q36036046-886A4610-5BB9-4D9F-AC3F-E4497EE39EE5 Q36068326-B19B4FF2-112D-49B7-9205-1FAF90865A84 Q36083385-CF8DA32D-9BC7-4E18-BB89-3C6D2BF0F823 Q36182645-C126F188-79F8-49A5-B7B7-40DABCE553CE Q36214081-B0A2BAA1-0B61-4299-88EF-5301DC5C51F6 Q36332012-422AEDF0-BCBD-447B-B301-DF94560CEFEB Q36972551-7896D9AA-E6B4-45DD-8045-C5949F4A4A1D Q37168778-FEE83D5E-C699-4577-A5B7-0BD367229ABD Q37240206-3F88B5DA-0AA5-4C1E-8835-D9CA1860521C Q37381182-CDBBC7A9-8398-4144-8408-0126031B9C5B Q37635839-940BA473-B4EE-40AB-B55E-5AFB9EB544F0 Q37647999-41BBCA96-A910-467B-800B-DA42198606C8 Q37680195-A7050EDF-71F3-4F24-A11C-50AC206F5086 Q37707078-7E3E2599-5384-4F66-8151-0DAF6D068D96

P2860

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

http://www.wikidata.org/entity/Q28476362

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@ast

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@en

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@nl

type

label

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@ast

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@en

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@nl

prefLabel

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@ast

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@en

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@nl

P1433

Q28476362-7966C4A2-2225-424D-8EA3-5C4D550093D5

P1476

Q28476362-7B89CE2B-7D74-4D16-82A7-1030D18A7461

P2093

Q28476362-35029BE0-0C79-4DE7-9A04-5C0D9AD3439A

Q28476362-47F2481D-FDEE-46EF-8DAF-20E64CA3BDD4

Q28476362-5A421453-22D3-4F27-9A4C-5A4C6D971278

Q28476362-69A13845-3240-40C2-8F6E-D1041BDB274A

Q28476362-6FAAAF30-82F6-46F0-9BF7-C2A732AA10BC

Q28476362-91E3C3C1-D0E9-4C59-93B9-7D39134691AA

Q28476362-9322AC7D-8AEB-4CF2-A52A-67E02D22DA59

Q28476362-959A2F50-CD3D-4BAA-8471-4027CC767B8A

Q28476362-BD0E2901-AD97-4275-BD38-5414FBDCEC0D

Q28476362-F3F0E736-87C3-48CA-814E-90186B6CDB9F

P2860

Q28476362-0ACB5B1B-A0B9-4F0A-B507-E4011AE4A97D

Q28476362-0CC4347A-2820-4874-9F5D-05A35755A7D4

Q28476362-0F4C4F61-2A53-4829-A1F7-AE0DF8F7812A

Q28476362-1761E04B-1184-4482-B7EE-DADFB53DD861

Q28476362-1881B93F-FFED-4AD3-99D5-BE7D9F6AFEB3

Q28476362-226528F4-DA27-4616-A903-C4E078983E5C

Q28476362-31AF2D4A-B33C-46DB-ABA8-12790FC45C0E

Q28476362-383CDCD0-3213-4CD7-819D-4BD806B374C2

Q28476362-42F38326-BEDD-452D-B1EB-7DB6BBDD411F

Q28476362-4AA1B65A-D72A-4AE3-B1F8-378D743C5491

P304

Q28476362-85DE2C34-B9B7-4764-9492-FB10F3032662

P31

Q28476362-D6E19951-2DE8-4398-B09B-B5560B5D7EBF

P356

Q28476362-29F9790A-43BE-4A5D-8B0B-D8356294ABBD

P407

Q28476362-7DE9F531-DD84-413D-9B8F-EEF7F079C656

P433

Q28476362-A2F065C1-670E-4AFE-B184-7ABC99F18CBE

P478

Q28476362-60562EB5-247D-480B-9AA4-07551E0B1470

P50

Q28476362-047B8F19-0BB6-443D-9499-3C54249C092E

Q28476362-0F269F87-028A-4596-9261-793A9C64EEE2

P577

Q28476362-1B7C0BE9-7150-4F79-8808-B98082F79BB4

P5875

Q28476362-BCA8030D-D6BF-424E-82D8-1D55DF555DCA

P698

Q28476362-DC65DD5C-9E7F-48B3-86BD-26C4A99BF95F

P932

Q28476362-1F8F8844-DD91-4E6E-B4AA-467C8C9CB52F

P356

JOURNAL.PONE.0014124

P1433

P1476

Combination treatment with MEK ...... ng cancer in vitro and in vivo

@en

P2093

B Nebiyou Bekele

http://www.w3.org/2001/XMLSchema#string

Bingbing Dai

http://www.w3.org/2001/XMLSchema#string

Bingliang Fang

http://www.w3.org/2001/XMLSchema#string

Duoli Sun

http://www.w3.org/2001/XMLSchema#string

Jack A Roth

http://www.w3.org/2001/XMLSchema#string

Jieru Meng

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

Michael Peyton

http://www.w3.org/2001/XMLSchema#string

William G Bornmann

http://www.w3.org/2001/XMLSchema#string

Zhenghong Peng

http://www.w3.org/2001/XMLSchema#string

P2860

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Regulation of cell death protease caspase-9 by phosphorylation

Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim

Drug combination studies and their synergy quantification using the Chou-Talalay method

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation.

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

P304

e14124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0014124

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Vassiliki Papadimitrakopoulou

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49651851

http://www.w3.org/2001/XMLSchema#string

P698

21124782

http://www.w3.org/2001/XMLSchema#string

P932

2993951

http://www.w3.org/2001/XMLSchema#string